Joint Clinical Trials Office
Targeting CD38 with Daratumumab in Primary Antiphospholipid Syndrome: A Phase 1b Dose Escalation Safety Trial
Study Status:
Open to Enrollment
Primary Investigator:
Date: April 2, 2024
Phase II Study of Suratadenoturev (OBP-301) in Combination with Pembrolizumab in Immunotherapy Refractory Esophagogastric Adenocarcinoma
Study Status:
Open to Enrollment
Primary Investigator:
Date: April 2, 2024
Comparison of Anti-coagulation and anti-Platelet Therapies for Intracranial Vascular Atherostenosis (CAPTIVA)
Study Status:
Open to Enrollment
Primary Investigator:
Date: April 17, 2024
A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, for Stroke Prevention after an Acute Ischemic Stroke or High-Risk TIA (LIBREXIA-STROKE)
Study Status:
Open to Enrollment
Primary Investigator:
Date: April 17, 2024
A Multicentre, Phase II, Open-label Study to Evaluate the Efficacy of Acalabrutinib in Combination with Venetoclax and Rituximab in Participants with Treatment Naïve Mantle Cell Lymphoma (TrAVeRse)
Study Status:
Open to Enrollment
Primary Investigator:
Date: April 23, 2024
A Phase 1, Open-Label, Multicenter, Dose Escalation and Expansion Study of KB707 in Subjects with Locally Advanced or Metastatic Solid Tumor Malignancies
Study Status:
Open to Enrollment
Primary Investigator:
Date: April 23, 2024
A Randomized Phase III Trial of Pre-Operative Compared to Post-Operative Stereotactic Radiosurgery in Patients with Resectable Brain Metastases
Study Status:
Open to Enrollment
Primary Investigator:
Date: April 23, 2024
Assessment of Placental Perfusion and Oxygenation Using Novel MRI Approaches
Study Status:
Open to Enrollment
Primary Investigator:
Date: May 7, 2024
Technical Development for Fetal and Neonatal MRI
Study Status:
Open to Enrollment
Primary Investigator:
Date: May 7, 2024
A Phase 3, Open-label, Randomised Study of Datopotamab Deruxtecan Versus Investigator’s Choice of Chemotherapy in Patients who are not Candidates for PD-1/PD-L1 Inhibitor Therapy in First-line Locally Recurrent Inoperable or Metastatic TNBC
Study Status:
Open to Enrollment
Primary Investigator:
Date: May 14, 2024